← Human Trials & Peer-Reviewed Studies
The effects of vitamin B12 supplementation on metabolic profile of patients with non-alcoholic fatty liver disease: a randomized controlled trial
Plain-language guide to PMID 35982162 (2022): double-blind randomized controlled trial study of Cyanocobalamin (Vitamin B12), fatty liver & elevated liver enzymes.
Key Facts
- PMID
- 35982162
- Journal
- Scientific reports
- Year
- 2022
- Study type
- Randomized Controlled Trial
- Authors
- Talari HR et al. (7 authors)
- DOI
- 10.1038/s41598-022-18195-8
What This Study Did, in Plain Language
What Was Tested
Researchers studied Cyanocobalamin (Vitamin B12) in the context of fatty liver & elevated liver enzymes in this randomized controlled trial publication.
The present study is the first effort to evaluate the effects of vitamin B12 supplementation on the serum level of liver enzymes, homocysteine, grade of hepatic steatosis, and metabolic profiles in patients with non-alcoholic fatty liver disease (NAFLD).
Why It Was Studied
The researchers investigated serum levels of homocysteine, aminotransferases, fasting blood glucose (FBG), lipids, malondialdehyde (MDA), and homeostasis model assessment of insulin resistance (HOMA-IR).
Who Took Part
The grade of liver steatosis and fibrosis was measured by real-time 2-dimensional shear wave elastography.
How the Study Was Run
The design is described as randomized, double-blind and placebo-controlled.
Random assignment meant chance, not the researchers, decided who got Cyanocobalamin (Vitamin B12) and who got the comparison, which limits bias.
As a double-blind Cyanocobalamin (Vitamin B12) study, the assignments were hidden from both participants and investigators until the end.
A placebo (an inactive look-alike) gave the Cyanocobalamin (Vitamin B12) group a baseline to be compared against.
What Was Measured
The researchers investigated serum levels of homocysteine, aminotransferases, fasting blood glucose (FBG), lipids, malondialdehyde (MDA), and homeostasis model assessment of insulin resistance (HOMA-IR).
Topics PubMed links to this paper include Blood Glucose, Dietary Supplements, Homocysteine, Metabolome, Non-alcoholic Fatty Liver Disease and Vitamin B 12.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Cyanocobalamin (Vitamin B12) in people with fatty liver & elevated liver enzymes.
The publication is from 2022 (Scientific reports), a journal based in England.
More context: the Cyanocobalamin (Vitamin B12) compound page, Fatty liver & elevated liver enzymes research.
Our Notes on the Compound
Cyanocobalamin (Vitamin B12): A synthetic form of vitamin B12 (cobalamin), an essential nutrient for DNA synthesis, red blood cell formation and neurological function.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.